Lorenzin Mariagrazia, Ometto Francesca, Ortolan Augusta, Felicetti Mara, Favero Marta, Doria Andrea, Ramonda Roberta
Rheumatology Unit, Department of Medicine -DIMED, University of Padova, Padova, Italy.
Rheumatology Unit, Department of Medicine -DIMED, University of Padova, Via Giustiniani 2, Padova, 35128, Italy.
Ther Adv Musculoskelet Dis. 2020 Jun 24;12:1759720X20934277. doi: 10.1177/1759720X20934277. eCollection 2020.
Axial spondyloarthritis (axSpA) is a group of debilitating, chronic, rheumatic conditions characterized by inflammation and new bone formation, mainly involving the spine and the sacroiliac joints. The lack of biomarkers in axSpA is well known. Despite significant treatment advances in recent years thanks to the introduction of drugs with a new mode of action, such as new biologic and targeted synthetic disease-modifying antirheumatic drugs, no relevant improvement in the identification of disease biomarkers has been achieved. Common parameters, such as erythrocyte sedimentation rate and C-reactive protein, which are routinely used to measure systemic inflammation, are the sole markers available to date and are not adequate to assess disease activity in all patients. The aim of this study is to review the most promising serum biomarkers that may help treatment decision in axSpA a proper assessment of disease activity and identification of negative prognostic factors.
轴性脊柱关节炎（axSpA）是一组使人衰弱的慢性风湿性疾病，其特征为炎症和新骨形成，主要累及脊柱和骶髂关节。axSpA缺乏生物标志物是众所周知的。尽管近年来由于引入了具有新作用模式的药物，如新型生物制剂和靶向合成改善病情抗风湿药，治疗取得了显著进展，但在疾病生物标志物的识别方面并未取得相关改善。常用参数，如红细胞沉降率和C反应蛋白，通常用于测量全身炎症，是目前仅有的可用标志物，不足以评估所有患者的疾病活动度。本研究的目的是综述最有前景的血清生物标志物，这些标志物可能有助于axSpA的治疗决策——对疾病活动度进行恰当评估并识别不良预后因素。
